ArticleFrontiers in oncology2025
Patient-derived organoid-guided precision therapy for a very young woman with multidrug-resistant metastatic breast cancer: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
- Patient-derived organoids in functional precision oncology: from experimental models to clinical decision-making.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reported a case of a 31-year-old female with therapy-resistant, refractory, and metastatic luminal B breast cancer. Using organoids derived from the patient's malignant pleural effusion for drug screening, we found that the combination of gemcitabine and cisplatin was the most sensitive, considering both IC50 and AUC values. In clinical practice, it was observed that the patient responded well to the selected treatment regimen, resulting in a significant reduction of pleural effusions, a marked decrease in tumor markers (e.g., CA125), and improved performance status (PS 2→1). The organoid model enabled the rational use of the patient's metabolic waste. It replicates the complexity of human tumors and facilitates extensive screening of beneficial drugs for patient diseases, particularly those with advanced tumors showing heterogeneity and rapid disease progression. This method swiftly identifies the optimal therapeutic drug regimen, minimizing the risk of drug resistance and trial costs, thereby providing maximum patient benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.